|
Key Points
|
208
|
|
Background
|
209
|
|
MATERIALS AND METHOD
|
211
|
|
RESULTS AND DISCUSSION
|
211
|
|
Epidemiology
|
211
|
|
Causes and Risk Factors
|
211
|
|
Associated Disorders Ordered by Importance
|
212
|
|
Complications Related to Prader-Willi Syndrome
|
213
|
|
Population at Risk or Screening Modalities
|
213
|
|
Preventive Measures
|
213
|
|
Clinical Presentation and Testing
|
213
|
|
Clinical Consensus Diagnostic Criteria
|
215
|
|
Laboratory Evaluation
|
215
|
|
Specific Genetic Laboratory Tests
|
217
|
|
Specific Clinic Testing
|
219
|
|
Other Obesity-related Disorders
|
221
|
|
Consultation for Diagnosis
|
224
|
|
Treatment and Medications
|
224
|
|
Vitamins and Other Supplements
|
232
|
|
Non-drug Treatments
|
233
|
|
CONCLUSION
|
236
|
|
Patient Satisfaction/Lifestyle Priorities
|
236
|
|
Consultation
|
236
|
|
Monitoring
|
237
|
|
Prognosis
|
237
|
|
Complications
|
238
|
|
Secondary Prevention/Patient Education
|
238
|
|
Practice Performance Measures/Summary of Evidence
|
239
|
|
Guidelines
|
239
|
|
Diagnostic Codes (ICD9-759.81 and ICD10-Q87.1) for Prader-Willi Syndrome
|
240
|
|
Clinical and Parent Questions
|
240
|
|
CONFLICT OF INTEREST
|
241
|
|
ACKNOWLEDGEMENTS
|
241
|
|
DISCLOSURE
|
241
|
|
REFERENCES
|
241
|
